Wednesday, September 7, 2011

weight loss

Acomplia Can Be The Deciding Factor In Reducing obesity




"How can Acomplia be the deciding factor in reducing obesity?" one may ask. By itself it cannot reduce or burn fats but it helps someone in reducing his or her food intake. It acts as an appetite suppressant. And as the appetite gets suppressed the food intake too lessens. But if it is taken in conjunction to physical exercises and a controlled diet program it can show a magnificent result in obesity reduction. Thus, infusion of Acomplia (Rimonabant) can be the deciding factor in reducing your obesity.

It is marketed by Sanofi-Aventis as Acomplia in UK and EU. And it is rumoured that if Acomplia (Rimonabant) gets FDA approval for sale in the USA it would be marketed as Zimulti. It is a weight loss drug discovered and developed by Sanofi-Aventis. It is a new class of CB1 blockers. It should be prescribed for persons who are with BMI of 30kg/m2 or more or overweight persons with 27kg/m2 with risk factors like dyslipidaemia or type 2 diabetes. As per their claim if Acomplia 20mg tablet is taken weight, waistline and triglycerides gets reduced plus it increases HDL- cholesterol levels.

It has mild and short term side effects like mood alteration with depressive disorders, dizziness, anxiety, nausea etc. Acomplia Diet Pills should not be initiated in obese individuals with renal or hepatic impairment or patients with psychiatric illness. One should consult a doctor before taking this drug as it is a prescription drug. Also remember that the individual results may vary.

If all the claims made by Sanofi-Aventis are true then it is a pill worth giving a look in your search for the ultimate weight loss pill. But as with any other diet pill it too requires controlled diet program and exercises. And when both of these act simultaneously with Acomplia (Rimonabant) it can work wonders for individuals with excess weight.





in Weight Loss



What now? Once you have read this article, give it a rating.

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home